
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells
Keywords: BER; base excision repair; BRCA1; breast cancer type 1 susceptibility protein; HMC; Hoffman modulation contrast; HR; homologous recombination; NER; nucleotide excision repair; NHEJ; non-homologous end joining; MMP; mitochondrial membrane potential; PARP-1